Toward unraveling the correlates of fatigue in glioma

Jantine G. Röttgering[1,2]*, Vera Belgers[2,3], Philip C. De Witt Hamer[2,4], Hans Knoop[1,5,6], Linda Douw[2,7], Martin Klein[1,2]

*Corresponding author, j.rottgering@amsterdamumc.nl, +31625005952, address: Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Psychology, Boelelaan 1117, Amsterdam, The Netherlands

[1] Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Psychology, Boelelaan 1117, Amsterdam, The Netherlands
[2] Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, The Netherlands
[3] Amsterdam UMC location Vrije Universiteit Amsterdam, Neurology, Boelelaan 1117, Amsterdam, The Netherlands
[4] Amsterdam UMC location Vrije Universiteit Amsterdam, Neurosurgery, Boelelaan 1117, Amsterdam, The Netherlands
[5] Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
[6] Amsterdam UMC location University of Amsterdam, Medical Psychology, Meibergdreef 9, Amsterdam, The Netherlands
[7] Amsterdam UMC location Vrije Universiteit Amsterdam, Anatomy and Neurosciences, Boelelaan 1117, Amsterdam, The Netherlands

Funding: Funding for this work was provided by the Stichting Anita Veldman Foundation (CCA-2019-2-21).

Conflict of interests: The authors declare that they have no competing interests.

Authorship

Conceptualization and design: JR, MK, LD. *Data collection and curation*: JR, VB. *Data analysis and interpretation*: JR, VB, LD, MK. *Visualization*: JR. *Writing of the manuscript*: JR. *Revising of the manuscript*: All authors. *Final approval of manuscript*: All authors. *Accountable for all aspects of the work*: All authors.

Abstract

Background: Even though fatigue is one of the most prevalent and burdensome symptoms in patients with glioma, its etiology and determinants are still poorly understood. We aimed to identify which demographic, tumor- and treatment-related characteristics and patient-reported outcome measures (PROMs) are associated with fatigue in glioma, and aimed to find predictors of postoperative fatigue.

Methods: In this retrospective cohort study, we collected data from patients with diffuse glioma who had performed preoperative and postoperative assessments consisting of PROMs on fatigue, depression, cognitive deficits, and health-related quality of life (HRQoL). Linear mixed models were used to identify which clinical factors and PROMs were associated with fatigue and linear multiple regression was used to find predictors of postoperative fatigue.

Results: In this study, 222 glioma patients were included, who had performed 333 assessments (193 preoperative and 116 postoperative). Of all assessments, 39% were indicative of severe fatigue. Several HRQoL domains, depression, and having a right-sided tumor were significantly associated with fatigue (marginal $R^2 = 0.63$). Contrary to common expectations, tumor type, treatment-related factors, the timing of the assessment, and disease status, were not associated with fatigue. In a subgroup of 70 patients with complete follow-up assessments, preoperative fatigue and self-reported physical functioning were predictors of postoperative fatigue (adjusted $R^2 = 0.31$).

Conclusion: Fatigue is a complex symptom, which should not solely be attributed to the tumor or its treatment, but is instead related to different aspects of mood and HRQoL. These insights are of importance in understanding fatigue and could guide symptom management.

Keywords

Fatigue; Patient Reported Outcome Measures; Brain Neoplasms; Quality of Life; Depression

Key points

Up to 40% of glioma patients are severely fatigued, regardless of disease status or tumor type.

HRQoL, depression, and right-sided tumor explain 63% of variance in fatigue severity.

Demographics, tumor type and treatment are not associated with fatigue severity.

Importance of the Study

Despite fatigue being one of the most frequent and burdensome symptoms in patients with glioma, its etiology remains poorly understood. In this study, we aimed to unravel the impact of demographic, tumor- and treatment-related factors, symptoms, and HRQoL to grasp the complexity of fatigue in a large cohort of 222 glioma patients with preoperative and postoperative assessments. Our findings demonstrate that fatigue is associated with several domains of HRQoL and depression, as well as a tumor in the right hemisphere. What stands out is that fatigue is not associated with disease status, tumor type, and treatment-related characteristics. These findings could be important in symptom management since tumor- and treatment-related factors are non-modifiable, whilst depressive symptoms and social and physical functioning could be more suitable treatment targets. These results underscore the need for symptom management focusing not only on fatigue but also on mood and diminished HRQoL.

Background

Patients with diffuse glioma experience a multitude of symptoms during the course of the disease including fatigue, cognitive impairment, and neurological deficits [1]. Fatigue is one of the most frequently reported and burdensome symptoms and is associated with a significant loss of health-related quality of life (HRQoL) [2]. The prevalence of fatigue fluctuates over time and reported numbers vary between studies [3]. Of the lower-grade glioma patients 39-77% report fatigue [4], while 48% of glioblastoma patients report fatigue after surgery, and this number increases to up to 90% in patients with tumor recurrence [5,6]. Because gliomas are still incurable and many patients suffer from fatigue and its sequelae, it is important to understand the interaction between fatigue and other symptoms and HRQoL to guide rational symptom management.

The etiology of fatigue in brain tumor patients is complex and poorly understood. Demographic, biomedical, neuropsychological, and psychosocial factors are thought to be related to fatigue [7]. It is unclear whether those factors are causally linked to the emergence and perpetuation of fatigue, or that symptom burden and diminished HRQoL are a result of severe fatigue. Several studies have reported conflicting variables to be associated with fatigue in glioma patients, often in small samples including different types of primary brain tumor patients at different time points during the disease. A relatively large study identified poor performance status, female sex, and disease status (active treatment versus stable disease) to be associated with fatigue in two-hundred primary brain tumor patients [8]. Contrarily, another study in 65 postoperative glioblastoma patients found that performance status was not associated with fatigue, but that depression played an important role [5]. Furthermore, two smaller studies in lower-grade glioma patients found that fatigued patients experienced more cognitive impairment, were older and used more anti-epileptic drugs [9,10]. It is important to note, that all these studies were cross-sectional and did not take longitudinal changes of fatigue into account, and thus did not investigate any potential predictors of fatigue.

Fatigue is also a prominent symptom in patients with cancer, cancer survivors, and patients with neurological diseases, including multiple sclerosis and Parkinson's disease [11,12]. A meta-analysis combined fifteen studies on fatigue in common chronic disorders and found that over half of all patients suffer from severe fatigue and that type of disease could only explain a small proportion of variance in fatigue severity [13]. Interestingly, when sex, age, motivational and concentration problems, pain, sleep disturbances, physical functioning, reduced activity and lower self-efficacy were added to the model, up to half of the variance in fatigue severity could be explained. The common denominator in those studies is that disease-specific factors were not associated with fatigue, whilst psycho-social symptoms, physical functioning and HRQoL were. It is not clear whether this would be the same in patients with glioma and whether tumor- and treatment-related factors play a role in glioma-related fatigue.

The current study aims to evaluate fatigue in a large cohort of glioma patients in relation to demographic, tumor- and treatment-related variables, as well as symptoms and HRQoL measured with patient-

reported outcome measures (PROMs). Furthermore, in a subset of patients with follow-up data, we aim to find predictors of postoperative fatigue and demonstrate how fatigue severity changes over time within the patient.

Methods

Participants and procedures

This is a retrospective observational cohort study in glioma patients at the Amsterdam UMC location Vrije Universiteit Amsterdam, a tertiary referral hospital in the Netherlands. Patients who were scheduled for tumor surgery were referred to the Department of Medical Psychology for an assessment. The assessments included questionnaires on fatigue, depression, self-perceived cognitive functioning, brain tumor-specific symptoms, and HRQoL. Patients were referred by their treating physician as part of routine clinical care. Of note, not all patients were referred for assessment, for example in case of emergency surgery or based on patient preference. One year after surgery, patients were invited to conduct the same assessment. This resulted in a varying number of assessments per patient, depending on the referral pattern and number of (re-)surgeries. Ethical approval for the use of clinical data for research purposes was granted by the Medical Ethics Review Committee (METc VUmc 2010.126) and written informed consent was obtained from the patients.

In this study, we included patients who performed one or multiple assessments between June 2010 and April 2021 and were diagnosed with diffuse glioma in the so-called **Glioma cohort**. Assessments with a missing fatigue questionnaire were excluded. A subset of patients of the *Glioma cohort* was included in the **Longitudinal subgroup**. These patients performed an assessment 0 to 6 months before surgery and 6 to 24 months after that same surgery, resulting in two assessments per patient within a specific timeframe.

Patient-reported outcome measures

Fatigue was assessed with the Checklist Individual Strength (CIS), a 20-item questionnaire answered on a seven-point Likert scale focusing on symptoms in the past two weeks [14]. The questionnaire consists of four subscales: fatigue severity (CIS-fatigue), concentration problems, reduced motivation, and reduced activity level. A validated cut-off of ≥35 on the CIS-fatigue subscale was used to indicate severe fatigue [14]. A change of ≥7 points on the CIS-fatigue subscale was defined as clinically relevant improvement or deterioration [15].

Depression was assessed with the Center for Epidemiologic Studies Depression questionnaire (CES-D) [16]. The Medical Outcomes Study Cognitive Functioning Scale (MOS-cog) was used to measure *self-perceived cognitive functioning* [17]. *Health-related quality of life* was assessed with the Medical Outcomes Study Short-Form Health Survey (SF-36). The SF-36 is organized into nine scales assessing physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/vitality, general health perceptions, and changes in health. In this study, we did not include the energy/vitality subscale. *Brain tumor-specific symptoms* were assessed with the European Organization for Research and Treatment of Cancer brain tumor module (BN20) questionnaire [18]. We only included the items future uncertainty,

motor dysfunction, and seizures in the analyses, because the other items were already assessed with the other questionnaires. All questionnaires were recoded and scored according to the relevant scoring manuals. A higher score of the CIS, CES-D, and BN-20 reflects more symptoms or problems, and a lower score of the MOS-cog and the SF-36 reflects more disability and worse functioning.

Statistical analysis

The scripts for the statistical analyses are available in an online repository on Github (https://github.com/multinetlab-amsterdam/projects/tree/master/fatigue_glioma_manuscript_2022). These scripts can be run with the provided mock data in the script. Analyses were conducted using R, version 4.0.3 [19]. Two-sided *p*-values < 0.05 were considered significant.

Our primary aim was to identify which demographic, tumor- and, treatment-related characteristics and PROMs were associated with fatigue severity in the *Glioma Cohort* with a linear mixed model (LMM). Patients were included as random intercepts, so we could control for the inclusion of multiple assessments per patient. We took three distinct steps: first, with univariate LMMs we evaluated associations between the CIS-fatigue score as a continuous variable and age, sex, education [20], KPS, location of the tumor, histology (oligodendroglioma, astrocytoma, oligoastrocytoma glioblastoma), isocitrate dehydrogenase (IDH) status (IDH mutation versus wildtype), disease status (pre-surgery, during treatment, stable, progression), the timing of the assessment (preoperative or postoperative), dexamethasone use (yes or no), radiotherapy before the assessment, chemotherapy before the assessment, and all PROMs. Secondly, factors with a statistically significant univariate association with fatigue were included in an LMM as independent variables. As the third and final step, we performed backward selection based on the Akaike Information Criterion to find the best-fitting model explaining variance in fatigue severity across patients.

Our secondary aim was to find predictors of postoperative fatigue. With the within-subject data of the *Longitudinal subgroup,* we computed a multiple linear regression model (MLRM) with clinical characteristics and preoperative PROMs as potential predictors. Again, we first evaluated univariate associations and then computed a final MLRM using backward selection with the postoperative CIS-fatigue as the dependent variable.

Furthermore, to assess within-subject similarity between preoperative and postoperative CIS-fatigue scores, we computed a two-way random effects single measure intraclass correlation coefficient with absolute agreement (ICC 2,1) [21]. The 95% confident interval of the ICC estimates was classified as poor (<0.5), moderate (0.5 – 0.75) or good (>0.75) [22].

<u>Results</u>

In this study, 222 patients with diffuse glioma were included in the *Glioma cohort* (Figure 1). They performed 343 assessments, of which ten were excluded due to missing CIS questionnaires. So in total,

we included 333 assessments (193 preoperative and 116 postoperative) in 222 patients. The mean age was 45 years and 57% were male. The majority of tumors were located in the left hemisphere (62%) and the frontal lobe (60%) and was classified as a WHO grade II (Table 1). The majority of patients used anti-epileptic drugs. A subset of 70 patients was included in the *Longitudinal subgroup* (Figure 1, Table 1), these patients completed a preoperative and a consecutive postoperative assessment.

Figure 1. Included patients and assessments in *Glioma cohort* and the *Longitudinal subgroup*

Abbreviations: Preop, preoperative assessment; Postop, postoperative assessment.

	Glioma cohort (N=222)	Longitudinal subgroup (n=70)
Age, mean (SD)	45.6 (13.3)	41.0 (11.6)
Sex, n (%)		

	Glioma cohort (N=222)	Longitudinal subgroup (n=70)
Male	126 (56.8%)	42 (60.0%)
Female	96 (43.2%)	28 (40.0%)
Level of education (Verhage), n (%)		
Low (1-4)	41 (18.5%)	11 (15.7%)
Middle (5)	75 (33.8%)	26 (37.1%)
High (6-7)	106 (47.7%)	32 (45.7%)
Missing		1 (1.4%)
Tumor hemisphere, n (%)		
Left	137 (61.7%)	46 (65.7%)
Right	81 (36.5%)	23 (32.9%)
Both	4 (1.8%)	1 (1.4%)
Tumor location, n (%)		
Frontal	132 (59.5%)	41 (58.6%)
Non-frontal	90 (40.5%)	29 (41.4%)
WHO grade, n (%)		
II	114 (51.4%)	47 (67.1%)
III	60 (27.0%)	20 (28.6%)
IV	48 (21.6%)	3 (4.3%)
Tumor type, n (%)		
Oligodendroglioma	74 (33.3%)	33 (47.1%)
Astrocytoma, IDH mutated	67 (30.2%)	24 (34.3%)
Astrocytoma, IDH wildtype	10 (4.5%)	3 (4.3%)
Astrocytoma, IDH status unknown	14 (6.3%)	3 (4.3%)
Oligoastrocytoma*	9 (4.1%)	4 (5.7%)
Glioblastoma, IDH mutated	5 (2.3%)	1 (1.4%)
Glioblastoma, IDH wildtype	21 (9.5%)	2 (2.9%)
Glioblastoma, IDH status unknown	22 (9.9%)	0 (0%)
Using anti-epileptic drugs, n (%)		
No	5 (2.3%)	1 (1.4%)
Yes	163 (73.4%)	52 (74.3%)
Missing	54 (24.3%)	17 (24.3%)
Number of included assessments per patient, n (%)		
1	137 (61.7%)	
2	68 (30.3%)	70 (100%)
3	10 (4.5%)	
4	6 (2.7%)	
6	1 (0.5%)	

Histological diagnosis of these patients was based on the 2007 WHO classification of the central nervous system tumors, and could not be re-classified because molecular markers were not available [23]
Abbreviations: SD, standard deviation; n, number.

Table 1. Sociodemographic and clinical characteristics *Glioma cohort* and *Longitudinal subgroup*

Prevalence of fatigue in the Glioma cohort and the Longitudinal subgroup

Of all assessments in the *Glioma cohort*, 39% (130/333) were indicative of severe fatigue, defined as a score of ≥35 on the CIS-fatigue subscale (Figure 2). Of the preoperative assessments 38% were classified as severely fatigued, and 41% of the postoperative assessments. During treatment, 37% of the assessments (30/81) were indicative of severe fatigue, and 43% (33/76) and 38% (9/24) of the assessments in patients with stable and progressive disease, respectively. In the *Longitudinal subgroup* preoperatively 34% and postoperatively 40% of the patients were severely fatigued. To clarify, in the *Glioma cohort* the percentages reflect the number of assessments indicative of severe fatigue, and not the number of patients since multiple assessments per patient were included. In the *Longitudinal subgroup*, the percentages do reflect the number of fatigued patients preoperatively and postoperatively.

Figure 2. Raincloud plots preoperative and postoperative Checklist Individual Strength
Each panel shows a raincloud plot, which is a combination of a scatterplot, a boxplot with median and interquartile range, and half a violin plot [24]. The grey lines between the dots of the scatterplots are combinations of scores of a preoperative and postoperative assessment within one patient. The grey dotted horizontal lines indicate the cut-off

scores for the scales with available validated cut-off values. All panels include all assessments of the Glioma cohort. Panel A reflects the Checklist Individual Strength (CIS) total score. Panels B-E reflect the four CIS subscales. Abbreviations: CIS, checklist individual strength.

Explaining variance in fatigue severity in the Glioma cohort

To identify factors that were associated with fatigue in the *Glioma cohort*, we computed an LMM with the aim of understanding which factors can explain variance in fatigue severity. First, with univariate comparisons, we determined which variables were independently associated with the CIS-fatigue score. There were no univariate associations between the CIS-fatigue score and age, dexamethasone use, chemotherapy, radiotherapy, tumor grade, histology, involved lobes, IDH status, disease status, and preoperative or postoperative assessment (Table 2). We did find univariate associations between the CIS-fatigue score and the SF-36 subscales, the BN20 items, CES-D, MOS-cog, sex, education, tumor hemisphere, and KPS. These variables were then included in an LMM. After backward selection, the final model included CES-D, four SF-36 subscales, and a tumor in the right hemisphere (Table 3). These variables were significantly associated with the CIS-fatigue score and together explained 63% of the variance in fatigue severity (marginal $R^2 = 0.63$).

Variable	N	Estimated Effect	Standard Error	T value	P value	Included in first LMM	Included in final LMM
SF36 subscales							
Physical functioning	324	-0.40	0.030	-13.3	<0.001	**Yes**	**Yes**
Role limitation - Physical	325	-0.19	0.013	-15.0	<0.001	**Yes**	**Yes**
General health perceptions	326	-0.34	0.029	-11.5	<0.001	**Yes**	**Yes**
Social functioning	331	-0.28	0.022	-12.9	<0.001	**Yes**	**Yes**
Role limitation - Emotional	322	-0.16	0.014	-10.9	<0.001	**Yes**	No
Mental health	328	-0.34	0.035	-9.5	<0.001	**Yes**	No
Bodily pain	327	-0.20	0.028	-7.1	<0.001	**Yes**	No
Change in health	332	-0.16	0.022	-7.2	<0.001	**Yes**	No
CES-D score depression	320	0.76	0.066	11.5	<0.001	**Yes**	**Yes**
Hemisphere, right	327	5.073	1.719	2.952	0.0035	**Yes**	**Yes**
KPS, 70-80 vs. 90-100	320	5.918	2.416	2.45	0.015	**Yes**	No
BN20 items/subscales							
Future uncertainty	322	0.22	0.025	8.99	<0.001	**Yes**	No
Motor dysfunction	328	0.35	0.039	9.02	<0.001	**Yes**	No
Seizures	331	0.12	0.023	5.25	<0.001	**Yes**	No
MOS-cog	332	-1.06	0.11	-9.43	<0.001	**Yes**	No
Female sex	333	5.95	1.63	3.65	<0.001	**Yes**	No
Verhage education, score 1-4 (low)	331						
Score 5 (middle)		-3.52	2.22	-1.58	0.12	No	
Score 6-7 (high)		-5.64	2.17	-2.59	0.01	**Yes**	No
Age	333	0.064	0.062	1.02	0.31	No	
Dexamethasone use	322	0.36	2.68	0.13	0.89	No	
IDH status	328	-2.42	2.60	-0.93	0.35	No	
Preoperative or postoperative assessment	333	1.25	1.21	1.04	0.30	No	
Had chemotherapy before assessment	333	1.34	1.66	0.81	0.42	No	
Had radiotherapy before assessment	333	2.04	1.44	1.41	0.16	No	
Tumor location, frontal	333						
Temporal		-0.10	2.056	-0.05	0.96	No	

Parietal		-1.44	2.424	-0.60	0.55	No
Parieto-temporal		1.28	4.996	0.26	0.80	No
Multi-focal and other		-6.29	5.114	-1.23	0.22	No
Histology, astrocytoma versus	333					
Oligodendroglioma		0.78	1.91	0.41	0.68	No
Oligoastrocytoma*		8.30	4.29	1.94	0.05	No
Glioblastoma		-1.40	2.23	-0.63	0.53	No
Disease status, baseline	333					
Treatment		-0.39	1.663	-0.23	0.82	No
Stable		1.32	1.562	0.85	0.40	No
Progression		-2.38	2.744	-0.87	0.39	No

Table 2. Associations between CIS-fatigue subscale and clinical factors and PROMs

For each variable, a Linear Mixed Model (LMM) was computed with CIS-fatigue as the dependent factor and patient as a random effect. For example, the SF-36 physical functioning subscale was significantly associated with the CIS-fatigue score. This variable was then included in the next step of the analysis and after backward selection remained included in the final LMM.

* Histological diagnosis of these patients was based on the 2007 WHO classification of the central nervous system tumors, and could not be re-classified because molecular markers were not available [23]

Abbreviations: CES-D, Center for Epidemiologic Studies Depression; CIS-fatigue, Checklist Individual Strength subscale fatigue severity; IDH, Isocitrate dehydrogenase; LMM, Linear mixed model; MOS-cog, Medical Outcomes Study Cognitive Functioning Scale; N, number; SF36, Medical Outcomes Study Short-Form Health Survey; BN20, The European Organization for Research and Treatment of Cancer brain tumor module.

Fixed effects	Estimated effect	Standard error	*T* value	*P* value
Intercept: CIS-fatigue	53.568	3.181	16.8	<0.001
SF-36 role limitation - physical	-0.086	0.015	-5.8	<0.001
SF-36 physical functioning	-0.169	0.032	-5.2	<0.001
SF-36 general health perceptions	-0.121	0.028	-4.3	<0.001
SF-36 social functioning	-0.054	0.026	-2.1	0.039
CES-D	0.234	0.069	3.4	<0.001
Right hemisphere	3.353	1.096	3.1	0.003

Table 3. HRQoL, depression, lesion in the right hemisphere associated with fatigue severity
This table shows the best-fit Linear Mixed Model with six variables explaining a large proportion of variance in the CIS-fatigue score. Patient was included as a random effect to control for multiple measurements.
Abbreviations: CES-D, Center for Epidemiologic Studies Depression; CIS-fatigue, Checklist Individual Strength subscale fatigue severity; SF-36, Medical Outcomes Study Short-Form Health Survey.

Within-subject changes and predictors of postoperative fatigue

To identify predictors of postoperative fatigue in the *Longitudinal cohort,* we computed univariate MLRMs with postoperative CIS-fatigue as the dependent variable. First, we identified that postoperative CIS-fatigue was significantly associated with the preoperative CIS subscales, SF-36 subscales, CES-

D, MOS-cog, and BN20 future uncertainty and motor dysfunction. There were no univariate associations between the postoperative CIS-fatigue scores and demographic and tumor- and treatment-related variables (Table S2). Then, these significantly associated variables were combined in an MLRM. After backward selection, the final model only included preoperative CIS-fatigue (estimated effect 0.32, p=0.02) and preoperative SF36 Physical Functioning (estimated effect -0.26, p=0.02) as significant predictors of postoperative CIS-fatigue. These two variables explained 31% of the variance of the postoperative CIS-fatigue score (adjusted R^2 = 0.31).

We also aimed to assess how within-subject fatigue changed over time. In this subgroup, CIS-fatigue scores improved postoperatively in 24% of the patients (17/70) and worsened in 30% (21/70, Figure 3). An ICC was calculated to assess within-patient similarity between the preoperative and postoperative assessments. The ICC was 0.522 (95% CI 0.329 - 0.673), which is classified as poor to moderate.

Figure 3. Improvement and deterioration of CIS-fatigue scores in the *Longitudinal subgroup*
The horizontal and vertical grey dashed lines reflect the cut-off score of 35 points. Deteriorating is defined as an increase in CIS-fatigue of ≥ 7, clinically significant improvement as a decrease in CIS-fatigue of ≥ 7 [15].

Discussion

The current study aimed to identify which demographic, tumor- and treatment characteristics and PROMs were associated with or were predictors of fatigue severity in a large cohort of glioma patients with multiple assessments. We showed that a large proportion of the variance in fatigue severity could be explained by patient-reported limitations in HRQoL, depressive symptoms, and a right-sided tumor. Preoperative fatigue and physical functioning were independent predictors of postoperative fatigue.

Interestingly, there were no univariate associations between the CIS-fatigue score and age, tumor type, treatment characteristics, disease status, or timing of the assessment. These results corroborate studies in brain tumor patients that found no link between fatigue and tumor location, disease duration, type of neurosurgical intervention, and radiation [8-10]. Also in cancer survivors and patients with chronic disease, the persistence of fatigue is not determined by tumor- and treatment-related characteristics [11,25-27]. Several transdiagnostic factors (i.e. factors that may account for fatigue found in multiple diseases), such as sleep disturbances, reduced physical functioning and activity, and lower self-efficacy concerning fatigue, underlie the differences between fatigued and non-fatigued patients [11,13,28]. Remarkably, a large Dutch population-based study demonstrated that the prevalence of fatigue is similar across several chronic diseases, and is associated with factors such as depression, female sex, younger age, lower education level, neuroticism, self-consciousness, impulsivity, vulnerability, and pain [11]. We also found several PROMs to be associated with fatigue, unlike tumor- and treatment-related factors. Functional and physical impairments have been identified as important determinants of fatigue and HRQoL before [8,29-31]. Depression is also known to be associated with fatigue in patients with cancer, meningioma, and neurological disease, with generally high correlations between the two [32-34].

We also found lesion laterality to be associated with fatigue. Tumor laterality has inconsistently been shown to be associated with HRQoL and symptoms like fatigue, depression and anxiety [35-37]. Also in stroke patients, there is no conclusive evidence on the association between fatigue and depression, and hemisphere and lesion location [38-40]. A recent study did show that right-hemisphere gliomas were associated with worse HRQoL, compared to left-hemisphere tumors [41]. The authors hypothesized that tumor infiltration in areas involved with controlling empathy could result in higher self-focus with diminished HRQoL as a result. Several models explain the possible hemispheric lateralization of emotions, for example how primary emotions are controlled by the right hemisphere and social emotion by the left hemisphere [42]. Perhaps these proposed mechanisms could also explain the association between fatigue and tumor laterality.

It is not evident whether fatigue is a direct result of depression and diminished HRQoL, or whether the association is bidirectional or even reversed. Future research should focus on why fatigue persists or emerges in some patients, while it decreases in others. Ecological momentary assessment might be a useful tool to answer this question and could be valuable in understanding the direction of the relation between fatigue and HRQoL and depression [43]. In the longitudinal subgroup, we identified preoperative

fatigue and physical functioning as independent predictors of postoperative fatigue. Fatigue at baseline has been identified as an important predictor of fatigue at follow-up in cancer patients before [44]. It could be of interest to understand whether mastery, or sense of control, coping style and catastrophizing are associated with fatigue in glioma patients. It is already known, that among patients with cancer a high sense of personal mastery is associated with less fatigue [45]. Also, decreased catastrophizing is a mediator in trials investigating the effectiveness of cognitive-behavioral therapy targeting fatigue [46].

Throughout this study, we have made a distinction between PROMs and demographic, and tumor- and treatment-related factors. This distinction is of importance in symptom management and when developing interventions targeting fatigue. Even though tumor- and treatment-related factors are important in disease management, these factors are usually non-modifiable and therefore not suitable as targets in ameliorating fatigue [47]. On the other hand, factors such as depression, social and physical functioning and health perception are indeed modifiable to some extent and therefore could be relevant targets. Since almost all patients in the current study used anti-epileptic drugs, we did not investigate the relation between anti-epileptic drugs and fatigue. It could be worthwhile to investigate this association since the type and dose of anti-epileptic drugs could also be a modifiable target [5,10] Currently, there are no evidence-based interventions targeting fatigue in glioma patients available [7]. There are several effective interventions targeting fatigue in cancer patients, including cognitive behavioral therapy, mindfulness, exercise, activity enhancement, problem-solving therapy, and acceptance and commitment therapy [26,48]. Those interventions might also be promising in treating fatigue in patients with glioma [48-50].

In the *Longitudinal subgroup*, about 40% of the patients reported severe fatigue preoperatively, and half of the patients showed clinical improvement or deterioration of the CIS-fatigue score. It is not known how changes in the CIS score during a long follow-up period reflect actual changes in everyday life in the individual patient. Even though the CIS questionnaire has a high test-retest reliability (r=0.74-0.86) [14], the questionnaire is validated for use in groups and not in individuals per se. To compare, in the Dutch population,15% of the patients without chronic disease report severe fatigue based on the CIS-fatigue score [11]. So it's evident, that the level of fatigue is much higher in glioma patients, compared to the general population.

One of the limitations of this study is the potential selection bias introduced by the procedure of active referral. Patients included in this study were referred to the Department of Medical Psychology by their treating physician. It is likely that physicians more often referred younger patients, patients with tumors in eloquent areas, or patients scheduled for awake craniotomy. Furthermore, caution is warranted since not all patients participated in follow-up assessments. The patients included in the longitudinal subgroup probably have a relatively favorable prognosis, compared to the general glioma population since almost all patients in the subgroup have a WHO grade II or III tumor and participated in follow-up. Despite this, it is pivotal to understand and treat fatigue after the initial treatment period since patients probably have more time to focus on symptom management after surgery, radiotherapy and chemotherapy.

In conclusion, the prevalence of fatigue is high throughout the disease in patients with diffuse glioma. Tumor type, treatment-related factors, the timing of the assessment, and disease status, were not associated with fatigue severity, whilst physical functioning, physical role limitations, general health perceptions, social functioning, depressive symptoms, and a right-sided tumor were. This demonstrates that fatigue is a complex symptom, that should not solely be contributed to the tumor itself or its treatment but is related to a broad range of symptoms. The interplay between fatigue, depression, and HRQoL factors, should be taken into account when providing care for fatigued glioma patients and when designing interventions to target fatigue.

Abbreviations

The European Organization for Research and Treatment of Cancer brain tumor module	BN20
Center for Epidemiologic Studies Depression	CES-D
Checklist Individual Strength	CIS
Checklist Individual Strength subscale fatigue severity	CIS-fatigue
Health-related quality of life	HRQoL
Intraclass correlation coefficient	ICC
Isocitrate dehydrogenase	IDH
Linear mixed model	LMM
Multiple linear regression model	MLRM
Medical Outcomes Study Cognitive Functioning Scale	MOS-cog
Patient-reported outcome measure	PROM
Medical Outcomes Study Short-Form Health Survey	SF-36

References

1. Taphoorn MJ, Sizoo EM, Bottomley A. Review on quality of life issues in patients with primary brain tumors. *Oncologist.* 2010; 15(6):618-626.

2. Gustafsson M, Edvardsson T, Ahlström G. The relationship between function, quality of life and coping in patients with low-grade gliomas. *Support Care Cancer.* 2006; 14(12):1205-1212.

3. M IJ-K, Snijders TJ, de Graeff A, Teunissen S, de Vos FYF. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. *Journal of neuro-oncology.* 2018; 140(3):485-496.

4. van Coevorden-van Loon EMP, Coomans MB, Heijenbrok-Kal MH, Ribbers GM, van den Bent MJ. Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence. *Journal of neuro-oncology.* 2017; 133(2):237-246.

5. Valko PO, Siddique A, Linsenmeier C, Zaugg K, Held U, Hofer S. Prevalence and predictors of fatigue in glioblastoma: a prospective study. *Neuro-Oncology.* 2014; 17(2):274-281.

6. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. *Neuro Oncol.* 2000; 2(4):221-228.

7. Asher A, Fu JB, Bailey C, Hughes JK. Fatigue among patients with brain tumors. *CNS Oncol.* 2016; 5(2):91-100.

8. Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. *Cancer.* 2010; 116(11):2707-2715.

9. van Coevorden-van Loon EMP, Heijenbrok-Kal MH, Horemans HLD, et al. The relationship between mental fatigue, cognitive functioning, and employment status in patients with low-grade glioma: a cross-sectional single-center study. *Disability and Rehabilitation.* 2021:1-7.

10. Struik K, Klein M, Heimans JJ, et al. Fatigue in low-grade glioma. *Journal of neuro-oncology.* 2009; 92(1):73-78.

11. Goërtz YMJ, Braamse AMJ, Spruit MA, et al. Fatigue in patients with chronic disease: results from the population-based Lifelines Cohort Study. *Scientific Reports.* 2021; 11(1):20977.

12. Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. *Neurology.* 2013; 80(4):409-416.

13. Menting J, Tack CJ, Bleijenberg G, et al. Is fatigue a disease-specific or generic symptom in chronic medical conditions? *Health Psychol.* 2018; 37(6):530-543.

14. Worm-Smeitink M, Gielissen M, Bloot L, et al. The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. *Journal of psychosomatic research.* 2017; 98:40-46.

15. Sobral Rebelo PF, Oliveira A, Paixão C, Marques A. Minimal clinically important difference for measures of fatigue, cough and sputum. *European Respiratory Journal.* 2019; 54(suppl 63):PA1216.

16. Radloff LS. The CES-D Scale:A Self-Report Depression Scale for Research in the General Population. *Applied Psychological Measurement.* 1977; 1(3):385-401.

17. Stewart A WJ, Jr, Sherbourne C, Wells K. Durham, NC. *Psychological distress/well-being and cognitive functioning measures.*: Duke University Press; 1992.

18. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. *European journal of cancer (Oxford, England : 1990).* 2010; 46(6):1033-1040.

19. (2020). RT. RStudio, PBC, Boston, MA. RStudio: Integrated Development Environment for R. 2020.

20. Verhage F. Intelligentie en Leeftijd Onderzoek bij Nederlanders van twaalf Tot Zevenenzeventig Jaar [Intelligence and Age: Research Study in Dutch Individuals Aged Twelve to Seventy-Seven]. 1964.

21. Matthias Gamer, Jim Lemon, Singh IFP. irr: Various Coefficients of Interrater Reliability and Agreement. 2019.

22. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. *Journal of Chiropractic Medicine.* 2016; 15(2):155-163.

23. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* 2007; 114(2):97-109.

24. Allen M, Poggiali D, Whitaker K, Marshall TR, Kievit RA. Raincloud plots: a multi-platform tool for robust data visualization. *Wellcome Open Res.* 2019; 4:63.

25. Schmidt ME, Chang-Claude J, Seibold P, et al. Determinants of long-term fatigue in breast cancer survivors: results of a prospective patient cohort study. *Psychooncology.* 2015; 24(1):40-46.

26. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. *Nature Reviews Clinical Oncology.* 2014; 11(10):597-609.

27. Maass SWMC, Brandenbarg D, Boerman LM, Verhaak PFM, de Bock GH, Berendsen AJ. Fatigue among Long-Term Breast Cancer Survivors: A Controlled Cross-Sectional Study. *Cancers.* 2021; 13(6):1301.

28. Nap-van der Vlist MM, Dalmeijer GW, Grootenhuis MA, et al. Fatigue among children with a chronic disease: a cross-sectional study. *BMJ Paediatrics Open.* 2021; 5(1):e000958.

29. Taveira FM, Braz NFT, Comini-Frota ER, Teixeira AL, Domingues RB. Disability as a determinant of fatigue in MS patients. *Arq Neuropsiquiatr.* 2019; 77(4):248-253.

30. Sturgeon JA, Darnall BD, Kao M-CJ, Mackey SC. Physical and Psychological Correlates of Fatigue and Physical Function: A Collaborative Health Outcomes Information Registry (CHOIR) Study. *The Journal of Pain.* 2015; 16(3):291-298.e291.

31. Lowry TJ, Pakenham KI. Health-related quality of life in chronic fatigue syndrome: predictors of physical functioning and psychological distress. *Psychol Health Med.* 2008; 13(2):222-238.

32. Brown LF, Kroenke K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. *Psychosomatics.* 2009; 50(5):440-447.

33. Skorvanek M, Gdovinova Z, Rosenberger J, et al. The associations between fatigue, apathy, and depression in Parkinson's disease. *Acta Neurol Scand.* 2015; 131(2):80-87.

34. van der Linden SD, Gehring K, Rutten GM, Kop WJ, Sitskoorn MM. Prevalence and correlates of fatigue in patients with meningioma before and after surgery. *Neuro-oncology practice.* 2020; 7(1):77-85.

35.   Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brain tumors: Current knowledge and future directions. *Neuro-Oncology.* 2009; 11(3):330-339.

36.   Palese A, Lamanna F, Di Monte C, Calligaris S, Doretto M, Criveller M. Quality of life in patients with right- or left-sided brain tumours: literature review. *J Clin Nurs.* 2008; 17(11):1403-1410.

37.   Mainio A, Hakko H, Niemelä A, Tuurinkoski T, Koivukangas J, Räsänen P. The effect of brain tumour laterality on anxiety levels among neurosurgical patients. *J Neurol Neurosurg Psychiatry.* 2003; 74(9):1278-1282.

38.   Kutlubaev MA, Duncan FH, Mead GE. Biological correlates of post-stroke fatigue: a systematic review. *Acta Neurologica Scandinavica.* 2012; 125(4):219-227.

39.   Ulrichsen KM, Kolskår KK, Richard G, et al. Structural brain disconnectivity mapping of post-stroke fatigue. *Neuroimage Clin.* 2021; 30:102635-102635.

40.   Bhogal SK, Teasell R, Foley N, Speechley M. Lesion Location and Poststroke Depression. *Stroke.* 2004; 35(3):794-802.

41.   Fortin D, Iorio-Morin C, Tellier A, Goffaux P, Descoteaux M, Whittingstall K. High-Grade Gliomas Located in the Right Hemisphere Are Associated With Worse Quality of Life. *World Neurosurgery.* 2021; 149:e721-e728.

42.   Ross ED. Differential Hemispheric Lateralization of Emotions and Related Display Behaviors: Emotion-Type Hypothesis. *Brain Sci.* 2021; 11(8).

43.   Kampshoff CS, Verdonck-de Leeuw IM, van Oijen MG, Sprangers MA, Buffart LM. Ecological momentary assessments among patients with cancer: A scoping review. *Eur J Cancer Care (Engl).* 2019; 28(3):e13095.

44.   Susanne K, Michael F, Thomas S, Peter E, Andreas H. Predictors of fatigue in cancer patients: a longitudinal study. *Supportive Care in Cancer.* 2019; 27(9):3463-3471.

45.   Jacobsen PB, Andrykowski MA, Thors CL. Relationship of catastrophizing to fatigue among women receiving treatment for breast cancer. *J Consult Clin Psychol.* 2004; 72(2):355-361.

46.   Müller F, Wijayanto F, Abrahams H, et al. Potential mechanisms of the fatigue-reducing effect of cognitive-behavioral therapy in cancer survivors: Three randomized controlled trials. *Psychooncology.* 2021; 30(9):1476-1484.

47.   Drijver AJ, Oort Q, Otten R, Reijneveld JC, Klein M. Is poor sleep quality associated with poor neurocognitive outcome in cancer survivors? A systematic review. *J Cancer Surviv.* 2022.

48.   Boele FW, Klein M, Reijneveld JC, Verdonck-de Leeuw IM, Heimans JJ. Symptom management and quality of life in glioma patients. *CNS Oncol.* 2014; 3(1):37-47.

49.   Röttgering JG, Douw L, de Witt Hamer PC, et al. Reducing severe fatigue in patients with diffuse glioma: a study protocol for an RCT on the effect of blended cognitive behavioural therapy. *Trials.* 2022; 23(1):568.

50.   Daun JT, Capozzi LC, Roldan Urgoiti G, et al. ACE-Neuro: A tailored exercise oncology program for neuro-oncology patients - Study protocol. *Contemp Clin Trials Commun.* 2022; 28:100925.